Kymeta Corporation Secures Approximately $85 Million Financing Round to Accelerate Growth, with Funding from Bill Gates
Kymeta Corporation (www.kymetacorp.com), the communications company making mobile global—is excited to announce the recapitalization of the company along with the successful funding raise of approximately $85 million, led by Bill Gates with members of the leadership team personally investing approximately $1 million led by Executive Chairman, Doug Hutcheson.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005257/en/
Image of Kymeta's next-generation terminal, the Kymeta™ u8. (Photo: Business Wire)
Since its launch of the revolutionary electronically steered flat panel antenna platform, Kymeta™ continues to strengthen and accelerate new product development and commercialization for satellite and cellular communications globally. Meeting the needs of current and future customers drives new product innovation and market development and are key areas of focus for Kymeta.
The financing builds on an extraordinary 18-month period for Kymeta, which saw a rapidly growing influx of new customers, the appointment of key executives, new product releases and market momentum in the areas of defense, public safety and land mobility. Kymeta’s channel network grew to include over one hundred reseller partners and several defense and commercial customers around the globe.
“As a company, we’re just scratching the surface of how powerful hybrid satellite-cellular communications can be when combined with an affordable electronically steered flat panel antenna offered to the global land mobility ecosystem,” said Doug Hutcheson, Executive Chairman, Kymeta. “Having the continued support of Bill Gates will help us execute our vision even more rapidly and broadly – and with the benefit of experience, perspective and relationships of a leading and highly successful technology backer.”
The new u8 terminal paired with Kymeta’s hybrid satellite-cellular connectivity services, Kymeta Connect™, transforms the purchase and consumption of mobile data with an all-inclusive hardware, connectivity and services monthly subscription. The Kymeta™ u8 is the world’s only commercially available flat panel electronically steered antenna built specifically for mobility and designed for the needs of military, first responders and commercial customers.
Key features and benefits of the Kymeta u8 terminal and Kymeta Connect platform also include 2 GHz support across the full Ku-Band, improved performance and efficiency which translates into lower total cost of ownership, integrated hybrid satellite-cellular hardware for always-on connectivity and turnkey Kymeta Connect options that include hardware, connectivity and service with affordable purchasing options.
Other announcements included were the acquisition of Lepton Global Solutions on August 18, 2020 and the Kymeta™ u8 beta trial program with select partners and customers globally, today.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, part of Kymeta, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best in class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta™ Connect services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005257/en/
Contact information
Business Inquiries for Kymeta:
Jon Maron
Vice President of Marketing and Communications
Kymeta Corporation
+1 425.658.8827
jmaron@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Associated Director PR, The Summit Group
+1 509.554.8409
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 09:00:00 EET | Press release
Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leading cause of business loss, the need for advanced security measures continues to grow. “Launching Vonage Silent Authentication API for the U.S. customers marks a tra
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 08:30:00 EET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 08:00:00 EET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple masterclasses and meet-the-expert sessions, and a booth that will delve into the science behind its innovations. “With ten posters spanning all key aesthetic treatment modalities and areas across the face and body, our data at IMCAS truly showcases the breadth and versatility of our injectable aesthetics portfolio and how we continue to drive innovation with our trusted products. In tandem with our first-class Galderma Aesthetic Injector Network (GAIN) educational activities, conducted in partnership with renowned experts, we are equ
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLD Symposium™ 202622.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study with oral nizubaglustat for late-infantile/juvenile GM2 and Niemann-Pick Type C diseases (RAINBOW) on February 5, presenting preliminary clinical efficacy and safety data. The data underscore nizubaglustat’s potential as a therapeutic option, reinforcing Azafaros’ commitment to addressing critical unmet needs in lysosomal storage disorders. Nizubaglustat reinstates pro-neuronal transcriptional programs in human CLN3 retinal organoidson February 6 (Rapid Fire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom